A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India) based regimen in metastatic gastric adenocarcinoma patients
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 20 Jan 2024 Results assessing safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium.
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 26 Jun 2018 New trial record